Analysts Maintain Bullish Outlook on Globe Life Shares

Market experts continue to express confidence in the prospects for life insurer Globe Life. A series of recent research reports highlight a sustained positive sentiment, reflected in numerous “Buy” ratings and upward revisions to price targets.

Upcoming Earnings in Focus

Attention is now turning to the company’s fourth-quarter 2025 results, scheduled for release after the market closes on February 4. These figures will serve as a crucial test for the company’s current performance and will be measured against analyst expectations. The broader optimistic view is grounded in a robust operating environment. Researchers anticipate life insurance premium growth of 4-5% and health insurance premium growth of 9-11%. Favorable demographic trends and a higher interest rate environment are seen as tailwinds for the business model.

Consensus and Price Targets

The analyst community shows a strong consensus. Currently, nine analysts rate the stock as a “Buy.” A previous report encompassing 19 researchers also arrived at a solid “Buy” consensus. The average price target stands at $161.89, implying an upside potential of approximately 17% from current trading levels. Individual targets reach as high as $199 per share.

Should investors sell immediately? Or is it worth buying Globe Life?

A Mixed Fundamental Picture

Globe Life’s third quarter included an exceptional pre-tax gain of $134.3 million, aided by favorable mortality experience in its life insurance segment. However, this positive one-time item contrasts with a generally subdued earnings outlook. For 2026, only moderate growth in operating earnings per share of about 3% is expected, a figure that sits below the historical average. Furthermore, some strategists note a concerning long-term decline in the company’s free-cash-flow conversion ratio.

Potential risks to the thesis are also noted. These include possible penalties from an ongoing review by the U.S. Equal Employment Opportunity Commission (EEOC), rising cost pressures within the health insurance business, and challenges in recruiting sales personnel.